<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19494" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Choriocarcinoma(Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bishop</surname>
            <given-names>Bradie N.</given-names>
          </name>
          <aff>Brooke Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Edemekong</surname>
            <given-names>Peter F.</given-names>
          </name>
          <aff>University of Texas Medical Branch - Galveston</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bradie Bishop declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Peter Edemekong declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19494.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gestational trophoblastic diseases were first described in 400 BC by Hippocrates.<xref ref-type="bibr" rid="article-19494.r1">[1]</xref>&#x000a0;Choriocarcinoma, a subtype of gestational trophoblastic disease,<xref ref-type="bibr" rid="article-19494.r2">[2]</xref>&#x000a0;is a rare and aggressive neoplasm.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref>&#x000a0;The 2 significant choriocarcinoma subtypes, namely: gestational and non-gestational, have very different biological activity and prognoses. Choriocarcinoma predominately&#x000a0;occurs in women but&#x000a0;can also occur in men, usually as part of a mixed germ cell tumor.</p>
      </sec>
      <sec id="article-19494.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Choriocarcinoma develops from an abnormal trophoblastic population undergoing hyperplasia and anaplasia, most frequently following a molar pregnancy.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref>&#x000a0;There are 2 forms of choriocarcinoma, gestational and non-gestational. The former arises following a hydatidiform mole, normal pregnancy, or most commonly, spontaneous abortion, while non-gestational choriocarcinoma arises from pluripotent germ cells.<xref ref-type="bibr" rid="article-19494.r4">[4]</xref> Non-gestational choriocarcinomas form in males or females, in the gonads, or midline structures with pluripotent germ cells.<xref ref-type="bibr" rid="article-19494.r4">[4]</xref></p>
      </sec>
      <sec id="article-19494.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Choriocarcinoma is a very rare neoplasm with varied incidence worldwide.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref>&#x000a0;In Europe and North America, about 1 in 40,000 pregnant patients and 1 in 40 patients with hydatidiform moles will develop choriocarcinoma.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref><xref ref-type="bibr" rid="article-19494.r5">[5]</xref>&#x000a0;In Southeast Asia and Japan,&#x000a0;9.2 in 40,000 pregnant women and 3.3 in 40 patients with hydatidiform moles will subsequently develop choriocarcinoma.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref>&#x000a0;In China, 1 in 2882 pregnant women will develop choriocarcinoma.<xref ref-type="bibr" rid="article-19494.r5">[5]</xref>&#x000a0;This correlates with an increased risk for the development of choriocarcinoma in Asian, American Indian, and African American women.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref>&#x000a0;Other risk factors include prior complete hydatidiform mole (a 100-fold increased risk), advanced age, long-term oral contraceptive use, and blood type A.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref></p>
        <p>Choriocarcinoma composes less than 0.1% of primary ovarian neoplasms in a pure form.<xref ref-type="bibr" rid="article-19494.r6">[6]</xref></p>
        <p>Choriocarcinoma can also occur in males, usually those between ages 20 to 30.<xref ref-type="bibr" rid="article-19494.r7">[7]</xref>&#x000a0;Less than 1% of testicular tumors are pure choriocarcinoma.<xref ref-type="bibr" rid="article-19494.r6">[6]</xref><xref ref-type="bibr" rid="article-19494.r7">[7]</xref>&#x000a0;Mixed germ cell tumors occur much more frequently in the testicle, with choriocarcinoma as a component in 15% of these tumors.<xref ref-type="bibr" rid="article-19494.r7">[7]</xref></p>
      </sec>
      <sec id="article-19494.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathogenesis of choriocarcinoma has not been fully explained or understood, but studies have shown cytotrophoblastic cells function as stem cells and undergo malignant transformation. The neoplastic cytotrophoblast further differentiates into intermediate trophoblasts and syncytiotrophoblast.<xref ref-type="bibr" rid="article-19494.r8">[8]</xref>&#x000a0;The mixture of cells mimics the normal development of a previllous blastocyst, a feature seen in other gestational trophoblastic neoplasms.<xref ref-type="bibr" rid="article-19494.r9">[9]</xref></p>
        <p>Overexpression of p53 and MDM2 have been demonstrated in choriocarcinoma, with no evidence of somatic mutation. Other genes implicated with either overexpression or down-regulation via hyper-methylation include NECC1, epidermal growth factor receptor, DOC-2/hDab2, Ras GTPase-activating protein, E-cadherin, HIC-1, p16, and TIMP3. HLA-G is demonstrated at very&#x000a0;high levels in choriocarcinoma and functions to change the tumor microenvironment through the inactivation of the local immune system.<xref ref-type="bibr" rid="article-19494.r9">[9]</xref></p>
      </sec>
      <sec id="article-19494.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Syncytiotrophoblasts, large eosinophilic smudgy multinucleated cells with known, large hyperchromatic nuclei,&#x000a0;are intermixed with cytotrophoblasts, polygonal cells with distinct borders, and single irregular nuclei.<xref ref-type="bibr" rid="article-19494.r7">[7]</xref>&#x000a0;Additionally, choriocarcinoma is an extremely vascular carcinoma characterized by necrosis and the absence of chorionic villi.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref></p>
        <p>Following chemotherapy, the cytotrophoblasts may predominate, making the diagnosis more difficult.&#x000a0;Within the uterus, choriocarcinoma&#x000a0;invades vessels to spread throughout the body, a relatively early finding.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref></p>
        <p>Intra-placental choriocarcinoma demonstrates trophoblast proliferation around villi in a third-trimester placenta, usually otherwise normal in appearance.<xref ref-type="bibr" rid="article-19494.r10">[10]</xref><xref ref-type="bibr" rid="article-19494.r11">[11]</xref></p>
        <p>In mixed germ cell tumors, choriocarcinoma will also have a mixture of syncytiotrophoblasts and cytotrophoblasts and varying components of other germ cell tumors.</p>
      </sec>
      <sec id="article-19494.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The healthcare professional should conduct a thorough history and physical examination of&#x000a0;any patient with suspected choriocarcinoma. In women, clinicians should pay particular attention to reproductive history because spontaneous abortions and molar pregnancies increase the risk for choriocarcinoma. One should consider post-menopausal bleeding suspicious. Choriocarcinoma tends to metastasize, and clinicians should note symptoms that arise from other organ systems, for example, hemoptysis or gastrointestinal (GI) bleeding.<xref ref-type="bibr" rid="article-19494.r5">[5]</xref></p>
        <p>Due to elevations in human chorionic gonadotropin (hCG) levels, patients can present with abnormal uterine bleeding, gynecomastia (in men), or hyperthyroidism.<xref ref-type="bibr" rid="article-19494.r6">[6]</xref></p>
        <p>Males will present can present with symptoms of metastatic disease, often hemoptysis, but the liver, GI tract, and brain are also frequently&#x000a0;involved.<xref ref-type="bibr" rid="article-19494.r7">[7]</xref></p>
      </sec>
      <sec id="article-19494.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Many laboratory tests can assess for choriocarcinoma, including complete blood count (CBC), coagulation studies, body chemistries, renal function panels, liver function panels, type and screen, and quantitative hCG.<xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
        <p>The United Kingdom registers and monitors all patients with hydatidiform or molar pregnancies and utilizes the following criteria to start chemotherapy for gestational trophoblastic disease:<xref ref-type="bibr" rid="article-19494.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Plateaued or rising hCG following uterine evacuation</p>
          </list-item>
          <list-item>
            <p>Heavy vaginal bleeding</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal or intraperitoneal bleeding</p>
          </list-item>
          <list-item>
            <p>Histologic evidence of choriocarcinoma</p>
          </list-item>
          <list-item>
            <p>Evidence of metastases in brain, liver, or gastrointestinal tract</p>
          </list-item>
          <list-item>
            <p>Lung opacities greater than 2 cm</p>
          </list-item>
          <list-item>
            <p>Serum hCG greater than 20,000 IU/L 4 weeks following evacuation</p>
          </list-item>
          <list-item>
            <p>Elevated hCG greater than 6 months after evacuation even when decreasing</p>
          </list-item>
        </list>
        <p>Following the diagnosis of choriocarcinoma, the healthcare professional should evaluate patients for metastasis; the lungs are the most common site for metastasis.<xref ref-type="bibr" rid="article-19494.r5">[5]</xref>&#x000a0;Chest, abdomen, and pelvic computed tomography are recommended in staging due to the highly metastatic nature of choriocarcinoma. Evaluate the brain via computer tomography or magnetic resonance imaging (MRI).<xref ref-type="bibr" rid="article-19494.r12">[12]</xref>&#x000a0;See <bold>Image.</bold>&#x000a0;Choriocarcinoma Metastasis to Brain.</p>
        <p>In males who have developed choriocarcinoma, the testicular anatomy is usually very small or even regressed, leaving only metastatic disease and cells.<xref ref-type="bibr" rid="article-19494.r7">[7]</xref></p>
      </sec>
      <sec id="article-19494.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>A low-risk (cumulative score less than 7, see staging section below) and stage I to III choriocarcinoma can be treated with a single agent, either methotrexate or actinomycin D chemotherapy.</p>
        <p>High-risk (a cumulative score greater than 7, see staging section below) and stage II to IV disease are treated with multi-agent chemotherapy, adjuvant radiation, and surgery.<xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
        <p>Following treatment and hCG normalization, quantitative hCG levels should be checked monthly for one year with a physical exam twice in the same time frame. If a subsequent pregnancy occurs, first-trimester pelvic ultrasound should be performed to confirm uterine location due to the small but present risk of recurrent choriocarcinoma; the placenta should&#x000a0;be submitted for histologic examination of recurrence.<xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
      </sec>
      <sec id="article-19494.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis includes:<xref ref-type="bibr" rid="article-19494.r3">[3]</xref><xref ref-type="bibr" rid="article-19494.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Placental site trophoblastic tumor</p>
          </list-item>
          <list-item>
            <p>Seminoma</p>
          </list-item>
          <list-item>
            <p>Mixed germ cell tumor</p>
          </list-item>
          <list-item>
            <p>Solid variant of yolk sac tumor</p>
          </list-item>
          <list-item>
            <p>Embryonal carcinoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19494.s10" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgical resection of either the uterus or metastatic foci is utilized in conjunction&#x000a0;with chemotherapy in approximately half of the patients with high-risk choriocarcinoma.<xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
      </sec>
      <sec id="article-19494.s11" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>The use of 3000 cGy, given&#x000a0;in 200 cGy fractions, is done for whole-brain irradiation of central nervous system (CNS) metastases.<xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
      </sec>
      <sec id="article-19494.s12" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>In the United States, low-risk (cumulative score less than 7, refer to staging section below) and stage I to III choriocarcinoma is treated with either methotrexate or actinomycin D chemotherapy with survival rates approaching 100%.</p>
        <p>In the United States and&#x000a0;the United&#x000a0;Kingdom, multi-agent chemotherapy with etoposide, actinomycin D, methotrexate,&#x000a0;folinic&#x000a0;acid, cyclophosphamide, and vincristine are utilized as&#x000a0;first-line treatment for patients with high-risk choriocarcinoma.<xref ref-type="bibr" rid="article-19494.r1">[1]</xref><xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
        <p>In the United Kingdom, gestational choriocarcinoma is usually treated with a combination of etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine.<xref ref-type="bibr" rid="article-19494.r1">[1]</xref>&#x000a0;If the patient has a large tumor load, induction therapy with etoposide and cisplatin has shown good results.<xref ref-type="bibr" rid="article-19494.r4">[4]</xref></p>
      </sec>
      <sec id="article-19494.s13" sec-type="Staging">
        <title>Staging</title>
        <p>The World Health Organization and International Federation of Gynecology and Obstetrics developed the following staging system for choriocarcinoma:<xref ref-type="bibr" rid="article-19494.r1">[1]</xref><xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I: Disease confined to the uterus</p>
          </list-item>
          <list-item>
            <p>Stage II: Disease extending beyond the uterus, but confined to genital structures</p>
          </list-item>
          <list-item>
            <p>Stage III: Disease extending to&#x000a0;the lungs</p>
          </list-item>
          <list-item>
            <p>Stage IV: Disease invading other metastatic sites</p>
          </list-item>
        </list>
        <p>
<bold>Criteria</bold>
</p>
        <p>Furthermore, the patients are then stratified into low- and high-risk groups to determine treatment based on the following criteria:</p>
        <p>
<bold>Age</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0: Younger than 39 years old</p>
          </list-item>
          <list-item>
            <p>1: Greater than 39 years old</p>
          </list-item>
        </list>
        <p>
<bold>Antecedent Pregnancy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0: Mole</p>
          </list-item>
          <list-item>
            <p>1: Abortion</p>
          </list-item>
          <list-item>
            <p>2: Term</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy Event to Treatment Interval</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0:&#x000a0;Less than 4 months</p>
          </list-item>
          <list-item>
            <p>1: 4 to 6 months</p>
          </list-item>
          <list-item>
            <p>2: 7 to 12 months</p>
          </list-item>
          <list-item>
            <p>4: Greater than 1 year</p>
          </list-item>
        </list>
        <p><bold>Pretreatment</bold><italic toggle="yes">&#x000a0;</italic><bold>hCG</bold> (mIU/ml)</p>
        <list list-type="bullet">
          <list-item>
            <p>0:&#x000a0;Less than 10^3</p>
          </list-item>
          <list-item>
            <p>1: 10^3 to 10^4</p>
          </list-item>
          <list-item>
            <p>2: 10^4 to 10^5</p>
          </list-item>
          <list-item>
            <p>4:&#x000a0;Greater than 10^5</p>
          </list-item>
        </list>
        <p>
<bold>Largest Tumor Mass</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0: Less than 3 cm</p>
          </list-item>
          <list-item>
            <p>1: 3 to 4 cm</p>
          </list-item>
          <list-item>
            <p>2:&#x000a0;Greater than 5 cm</p>
          </list-item>
        </list>
        <p>
<bold>Site of Metastases</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0: None</p>
          </list-item>
          <list-item>
            <p>1: Spleen, kidney</p>
          </list-item>
          <list-item>
            <p>2: GI tract</p>
          </list-item>
          <list-item>
            <p>4: Brain, liver</p>
          </list-item>
        </list>
        <p>
<bold>Number of Metastases</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0: None</p>
          </list-item>
          <list-item>
            <p>1: 1 to 4</p>
          </list-item>
          <list-item>
            <p>2: 5 to 8</p>
          </list-item>
          <list-item>
            <p>4: Greater than 8</p>
          </list-item>
        </list>
        <p>
<bold>Previous Failed Chemotherapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0: None</p>
          </list-item>
          <list-item>
            <p>2: Single-drug</p>
          </list-item>
          <list-item>
            <p>4: Greater than&#x000a0;2 drugs</p>
          </list-item>
        </list>
        <p>
<bold>Cumulative Score</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Low-risk: Less than 7</p>
          </list-item>
          <list-item>
            <p>High-risk: Greater than 7</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19494.s14" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Gestational choriocarcinoma and non-gestational choriocarcinoma have different prognoses, with non-gestational choriocarcinoma having a much worse prognosis.<xref ref-type="bibr" rid="article-19494.r4">[4]</xref><xref ref-type="bibr" rid="article-19494.r13">[13]</xref> The latter is also much less chemosensitive. Genotyping highlights the difference in gestational and non-gestational choriocarcinoma; gestational choriocarcinoma usually has a paternal chromosome complement while non-gestational choriocarcinoma has DNA that matches the patient, with occasional karyotype abnormalities.<xref ref-type="bibr" rid="article-19494.r13">[13]</xref></p>
        <p>Low-risk gestational choriocarcinoma has almost 100% survival in women treated with chemotherapy, and high-risk gestational choriocarcinoma patients have 91% to 93% survival when utilizing multi-agent chemotherapy with or without radiation and surgery. Adverse risk factors making death more likely include stage IV disease or a cumulative score greater than 12 in women.<xref ref-type="bibr" rid="article-19494.r12">[12]</xref></p>
        <p>In men with mixed germ cell tumors,&#x000a0;increasing amounts of choriocarcinoma portend&#x000a0;a worse prognosis, with pure choriocarcinomas having the worst prognosis in testicular germ cell neoplasms. An hCG greater than 50,000 mIU/ml also correlates to a worse prognosis in men.<xref ref-type="bibr" rid="article-19494.r7">[7]</xref></p>
        <p>Intra-placental choriocarcinoma with metastasis to the infant carries a very poor prognosis, with less than 20% survival.<xref ref-type="bibr" rid="article-19494.r10">[10]</xref></p>
      </sec>
      <sec id="article-19494.s15" sec-type="Complications">
        <title>Complications</title>
        <p>Without treatment, choriocarcinoma can result in death. With the advent of&#x000a0;chemotherapy, many patients can achieve remission and cure of their disease. The utilization of chemotherapy is not without its risks, including the development of secondary malignancies, nausea, vomiting, hair loss, diarrhea, fevers, infections, and the need for transfusion of blood productions.</p>
      </sec>
      <sec id="article-19494.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Women who experience a molar pregnancy, whether complete or incomplete, should be counseled as to the risk for the development of choriocarcinoma. These patients should be monitored&#x000a0;closely&#x000a0;for resolution of their hCG levels. Any woman who has given birth, but particularly if she is a high risk, should be counseled to return for continued post-partum bleeding.</p>
      </sec>
      <sec id="article-19494.s17" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="order">
          <list-item>
            <p>Elevated hCG levels in a woman without confirmed intrauterine pregnancy should prompt a search for both ectopic pregnancy and the possibility of a malignancy secreting hCG. Lack of response to methotrexate makes a malignancy much more likely.<xref ref-type="bibr" rid="article-19494.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>False-positive elevations in hCG can be due to heterophile (human anti-mouse) antibodies and should be considered before treating patients surgically or with systemic chemotherapy.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>In men, choriocarcinoma usually occurs as part of a mixed germ cell tumor; when occurring in a pure form, the primary tumor may be very small or even regressed while symptoms are all related to metastasis.<xref ref-type="bibr" rid="article-19494.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Intra-placental choriocarcinoma is a very rare variant usually, presenting with metastatic symptoms in the post-partum mother, and rarely with metastasis in the infant, and should be included on the differential diagnosis of elevated AFP in a postpartum patient.<xref ref-type="bibr" rid="article-19494.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19494.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians taking care of patients following molar pregnancy should remain aware and vigilant of the pitfall of heterophile (human anti-mouse) antibodies occurring in 3% to 4% of patients, resulting in falsely positive elevated hCG.&#x000a0;The presence of heterophile antibodies can&#x000a0;be teased out by serial dilution of serum, which will not show a parallel decrease with dilution or sending of serum and patient urine to a reference hCG laboratory.<xref ref-type="bibr" rid="article-19494.r3">[3]</xref></p>
        <p>High clinical suspicion should be maintained for choriocarcinoma in women with hemoptysis and molar pregnancy, current, or recent pregnancy, or irregular vaginal bleeding.<xref ref-type="bibr" rid="article-19494.r5">[5]</xref>&#x000a0;An interprofessional treatment center with nurses and clinicians specializing in gestational trophoblastic disease&#x000a0;is beneficial to improving outcomes. [Level 1 and 2]</p>
      </sec>
      <sec id="article-19494.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19494&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19494">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19494/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19494">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19494.s20">
        <fig id="article-19494.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Choriocarcinoma Metastasis to the Brain Contributed by S Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CHRIO" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19494.s21">
        <title>References</title>
        <ref id="article-19494.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seckl</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sebire</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Gestational trophoblastic disease.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Aug</month>
            <day>28</day>
            <volume>376</volume>
            <issue>9742</issue>
            <fpage>717</fpage>
            <page-range>717-29</page-range>
            <pub-id pub-id-type="pmid">20673583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bruce</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sorosky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Gestational Trophoblastic Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">29261918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lurain</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>203</volume>
            <issue>6</issue>
            <fpage>531</fpage>
            <page-range>531-9</page-range>
            <pub-id pub-id-type="pmid">20728069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stockton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>De Winton</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Non-Gestational Choriocarcinoma with Widespread Metastases Presenting with Type 1 Respiratory Failure in a 39-Year-Old Female: Case Report and Review of the Literature.</article-title>
            <source>Case Rep Oncol</source>
            <year>2018</year>
            <season>Jan-Apr</season>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>151</fpage>
            <page-range>151-158</page-range>
            <pub-id pub-id-type="pmid">29681814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Hemoptysis as primary manifestation in three women with choriocarcinoma with pulmonary metastasis: a case series.</article-title>
            <source>J Med Case Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <day>16</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <pub-id pub-id-type="pmid">28411623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ulbright</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.</article-title>
            <source>Mod Pathol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>18 Suppl 2</volume>
            <fpage>S61</fpage>
            <page-range>S61-79</page-range>
            <pub-id pub-id-type="pmid">15761467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali</surname>
                <given-names>TZ</given-names>
              </name>
              <name>
                <surname>Parwani</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Benign and Malignant Neoplasms of the Testis and Paratesticular Tissue.</article-title>
            <source>Surg Pathol Clin</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-159</page-range>
            <pub-id pub-id-type="pmid">26838100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mao</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Kurman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>IeM</given-names>
              </name>
            </person-group>
            <article-title>Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>1726</fpage>
            <page-range>1726-32</page-range>
            <pub-id pub-id-type="pmid">18059230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shih</surname>
                <given-names>IeM</given-names>
              </name>
            </person-group>
            <article-title>Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets.</article-title>
            <source>Lancet Oncol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>642</fpage>
            <page-range>642-50</page-range>
            <pub-id pub-id-type="pmid">17613426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature.</article-title>
            <source>Gynecol Oncol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>1147</fpage>
            <page-range>1147-51</page-range>
            <pub-id pub-id-type="pmid">17005243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heller</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Update on the pathology of gestational trophoblastic disease.</article-title>
            <source>APMIS</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>126</volume>
            <issue>7</issue>
            <fpage>647</fpage>
            <page-range>647-654</page-range>
            <pub-id pub-id-type="pmid">30129126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lurain</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>204</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-8</page-range>
            <pub-id pub-id-type="pmid">20739008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Veras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ronnett</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Choriocarcinoma in Women: Analysis of a Case Series With Genotyping.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>12</issue>
            <fpage>1593</fpage>
            <page-range>1593-1606</page-range>
            <pub-id pub-id-type="pmid">28877059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19494.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larish</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Langstraat</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Primary Gastric Choriocarcinoma Presenting as a Pregnancy of Unknown Location.</article-title>
            <source>Obstet Gynecol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>129</volume>
            <issue>2</issue>
            <fpage>281</fpage>
            <page-range>281-284</page-range>
            <pub-id pub-id-type="pmid">28079767</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
